7月15日，派格生物医药-B盘中上涨8.78%，报6.82港元，成交额7200.29万港元。公司此前因与纳斯达克上市公司Rani Therapeutics签署谅解备忘录，股价于7月10日大涨约29%，7月13日续涨逾4%后，7月14日因获利盘集中兑现回调约8%，本次上涨系短期超跌后的技术性修复。
该谅解备忘录有效期三年，双方将依托Rani专有的RaniPill口服生物药递送平台，围绕派格生物多项肥胖症及代谢疾病候选资产开展口服制剂筛选及临床前开发，并探索中国以外市场的商业化合作。当日生物科技板块整体走强，科伦博泰生物涨7.69%、康方生物涨6.1%，板块情绪对个股形成支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.